ClinicalTrials.gg
Enrolling by invitationNCT07061691Updated Oct 22, 2026

WIM Exosuit Wearable Soft Robot for Enhancing Walking Activity

An interventional study of WIM Robotic Exoskeleton in Stroke and Healthy, sponsored by Shirley Ryan AbilityLab. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now Enrolling by invitationGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Stroke by Shirley Ryan AbilityLab — 12 open to participants now, 20 under way, none of them phase 3. Stroke · Shirley Ryan AbilityLab.

Planned enrollment
36th of 55
20 · median 30
Started
2025
with 3 others
No phase
49 of 64
10 open now
Primary completion
2028-07
later than 18 of 19 live
Registered
63rd of 64
by date

Among the 64 studies in Stroke by Shirley Ryan AbilityLab, this one is the 36th largest by planned enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 49 with no phase, reaches primary completion later than 18 of the 19 other live ones, and was the 63rd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

12 of the 64 studies in Stroke by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Stroke by Shirley Ryan AbilityLab, or all of them as a file.
02

Study summary

This study is to develop, test, and optimize a soft hip wearable robot for individuals with stroke, Parkinson's, multiple sclerosis, or older adults with no neurologic deficits.

03

Conditions studied

  • Stroke
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Be at least 6 months post-stroke, have a diagnosis of Parkinson's, have a diagnosis of multiple sclerosis, or an adult older than 65 with no known neurological diagnoses.

For the Optimization Aim of the study, Participants may also be healthy individuals with no known impairments.

  • Age: 18-89 years of age
  • For stroke, Parkinson's, multiple sclerosis, or older adult participants, must have adequate cognitive function ( score >17)
  • Ability to walk at least 10 meters with maximum of 1 person assist
  • Able to safely fit into the WIM exosuit, which is confirmed via an in-person fitting..

Exclusion criteria

Exclusion Criteria:

  • - \<90 days post major orthopedic surgery (i.e. hip, knee, and/or ankle joint replacement.)
  • \< 6 months post CABG or cardiac valve procedure
  • Any skin irritations / conditions that may preclude a participant from tolerating the use of the exosuit.
  • Severe osteoporosis, defined as osteoporosis that has been diagnosed and a participant's doctor has recommended pharmacologic treatment, or there is both a history of osteoporosis and a history of fractures.
  • Serious cardiac conditions, such as hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living.
  • Pregnancy
  • Uncontrolled hypertension (resting systolic blood pressure greater than or equal to 150, or resting diastolic pressure greater than or equal to 90.) If a participant demonstrates a BP greater than these values, then the participant will sit quietly for 5 mins, and then be re-checked. If the BP values remain over those thresholds, then the participant will be excluded. Individuals in such situations may return to be re-screened for participation after they follow up with their physician and the hypertension is better controlled.
  • Lower extremity fracture, either currently or within the past 6 months.
  • Modified Ashworth Spasticity (MAS) scores of ≥ 3 in hip flexors or extensors, if the participant is post-stroke or multiple sclerosis.
  • Pre-existing neurological disorders such as amyotrophic lateral sclerosis (ALS), dementia
  • History of major head trauma, lower extremity amputation, non-healing ulcers of a lower extremity, ongoing active infections, legal blindness, or a history of significant psychiatric illness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Healthy Population

    Device: WIM Robotic Exoskeleton

Interventions

  • DeviceWIM Robotic Exoskeleton

    Wearable hip-powered exoskeleton

06

What researchers measure

Primary outcomes

  1. 6-minute walk test

    Primary outcome for Optimization aim of study.

    Time frame: Baseline (Single-session)

  2. Metabolic Cost

    Primary outcome for Optimization aim of study. Data collected using Cosmed K5 Metabolic Unit

    Time frame: Baseline (single session)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 36 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 11, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 22, 2026
Contact
No study contact listed any more: removed k•••@sralab.org · •••8312
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Enrolling by invitation
    Contact No study contact listed any more: removed k•••@sralab.org · •••8312
    + 3 other changes: verification date, description and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07061691
Responsible party
Arun Jayaraman, PT, PhD (Principal Investigator:Arun Jayaraman, PT, PhD,Shirley Ryan AbilityLab, Shirley Ryan AbilityLab) — Principal investigator
First posted
Jul 11, 2025
Start date
Jul 7, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion